Patents by Inventor Steven Alan Stacker

Steven Alan Stacker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of enhancing the acceptance and/or healing of a skin graft
    Patent number: 8461109
    Abstract: The invention also relates to a method for of enhancing the acceptance and/or healing of a skin graft in a subject comprising stimulating angiogenesis and lymphangiogenesis with an effective amount of an isolated VEGF-D polypeptide.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: June 11, 2013
    Assignee: Vegenics Pty Limited
    Inventors: Marc G. Achen, Steven Alan Stacker, Kari Alitalo
  • Expression Vectors and Cell Lines Expressing Vascular Endothelial Growth Factor D, and Method of Treating Melanomas
    Publication number: 20120270781
    Abstract: This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases.
    Type: Application
    Filed: April 17, 2012
    Publication date: October 25, 2012
    Applicant: VEGENICS PTY LIMITED
    Inventors: Marc G. Achen, Steven Alan Stacker, Kari Alitalo
  • Expression Vectors and Cell Lines Expressing Vascular Endothelial Growth Factor D, and Method of Treating Melanomas
    Publication number: 20110269146
    Abstract: This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases.
    Type: Application
    Filed: November 5, 2010
    Publication date: November 3, 2011
    Applicant: VEGENICS LIMITED
    Inventors: Marc G. Achen, Steven Alan Stacker, Kari Alitalo
  • Chimeric Anti-VEGF-D Antibodies and Humanized Anti-VEGF-D Antibodies and Methods of Using the Same
    Publication number: 20110189170
    Abstract: The present invention relates to materials and methods for modulating angiogenesis and lymphangiogenesis. The compositions of the invention provide chimeric and/or humanized VEGF-D antibody substances, antibodies, polypeptides and fragments thereof useful for modulating angiogenesis and lymphangiogenesis in a subject.
    Type: Application
    Filed: December 3, 2010
    Publication date: August 4, 2011
    Applicant: VEGENICS LIMITED
    Inventors: MARC GREGORY ACHEN, STEVEN ALAN STACKER, CHRISTOPH RENNER
  • Expression vectors and cell lines expressing vascular endothelial growth factor D
    Patent number: 7947472
    Abstract: This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases.
    Type: Grant
    Filed: December 23, 1998
    Date of Patent: May 24, 2011
    Assignee: Vegenics Limited
    Inventors: Marc G. Achen, Steven Alan Stacker, Kari Alitalo
  • EXPRESSION VECTORS AND CELL LINES EXPRESSING VASCULAR ENDOTHELIAL GROWTH FACTOR D, AND METHOD OF TREATING MELANOMAS
    Publication number: 20110059890
    Abstract: This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases.
    Type: Application
    Filed: October 12, 2009
    Publication date: March 10, 2011
    Applicant: VEGENICS LIMITED
    Inventors: MARC G. ACHEN, STEVEN ALAN STACKER, KARI ALITALO
  • Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
    Patent number: 7846437
    Abstract: The present invention relates to materials and methods for modulating angiogenesis and lymphangiogenesis. The compositions of the invention provide chimeric and/or humanized VEGF-D antibody substances, antibodies, polypeptides and fragments thereof useful for modulating angiogenesis and lymphangiogenesis in a subject.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: December 7, 2010
    Assignee: Vegenics Limited
    Inventors: Marc Gregory Achen, Steven Alan Stacker, Christoph Renner
  • CHIMERIC ANTI-VEGF-D ANTIBODIES AND HUMANIZED ANTI-VEGF-D ANTIBODIES AND METHODS OF USING SAME
    Publication number: 20090155252
    Abstract: The present invention relates to materials and methods for modulating angiogenesis and lymphangiogenesis. The compositions of the invention provide chimeric and/or humanized VEGF-D antibody substances, antibodies, polypeptides and fragments thereof useful for modulating angiogenesis and lymphangiogenesis in a subject.
    Type: Application
    Filed: June 30, 2008
    Publication date: June 18, 2009
    Applicant: VEGENICS LIMITED
    Inventors: Marc Gregory Achen, Steven Alan Stacker, Christoph Renner
  • Antibodies to truncated VEGF-D and uses thereof
    Patent number: 7097986
    Abstract: The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the binding of VEGF-D to VEGFR-3 but does not interfere with the activity of VEGF mediated by VEGFR-2 or bind to VEGF-C. The invention provides pharmaceutical and diagnostic compositions and methods utilizing these antibodies.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: August 29, 2006
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Marc G. Achen, Steven Alan Stacker
  • Antibodies to truncated VEGF-D and uses thereof
    Publication number: 20040141917
    Abstract: The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the binding of VEGF-D to VEGFR-3 but does not interfere with the activity of VEGF mediated by VEGFR-2 or bind to VEGF-C. The invention provides pharmaceutical and diagnostic compositions and methods utilizing these antibodies.
    Type: Application
    Filed: February 18, 2004
    Publication date: July 22, 2004
    Applicant: Ludwig Institute for Cancer Research
    Inventors: Marc G. Achen, Steven Alan Stacker
  • Antibodies to truncated VEGF-D and uses thereof
    Patent number: 6730489
    Abstract: The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the binding of VEGF-D to VEGFR-3 but does not interfere with the activity of VEGF mediated by VEGFR-2 or bind to VEGF-C. The invention provides pharmaceutical and diagnostic compositions and methods utilizing these antibodies.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: May 4, 2004
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Marc G. Achen, Steven Alan Stacker
  • Preventing secondary lymphedema with VEGF-D DNA
    Publication number: 20030228283
    Abstract: Methods of preventing secondary lymphedema with DNA encoding VEGF-D and/or VEGF-D protein, and biologically active fragments and analogs thereof, as well as pharmaceutical compositions for treating secondary lymphedema, are presented.
    Type: Application
    Filed: April 29, 2003
    Publication date: December 11, 2003
    Applicant: Ludwig Institute for Cancer Research
    Inventors: Lucie Margarete Heinzerling, Megan Elizabeth Baldwin, Steven Alan Stacker, Maro Gregory Achen
  • EXPRESSION VECTORS AND CELL LINES EXPRESSING VASCULAR ENDOTHELIAL GROWTH FACTOR D, AND METHOD OF TREATING MELANOMAS
    Publication number: 20020127222
    Abstract: This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases.
    Type: Application
    Filed: December 23, 1998
    Publication date: September 12, 2002
    Inventors: MARC G. ACHEN, STEVEN ALAN STACKER, KARI ALITALO
  • Antibodies to truncated VEGF-D and thereof
    Patent number: 6383484
    Abstract: The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the binding of VEGF-D to VEGFR-3 but does not interfere with the activity of VEGF mediated by VEGFR-2 or bind to VEGF-C. The invention provides pharmaceutical and diagnostic compositions and methods utilizing these antibodies.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: May 7, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Marc G. Achen, Steven Alan Stacker